For Immediate Release
Chicago, IL – April 22, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson
JNJ
, Roche Holding AG
RHHBY
, Raytheon Technologies Corp.
RTX
, Intuit Inc.
INTU
and Target Corp.
TGT
.
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Johnson & Johnson, Roche and Raytheon
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Roche Holding AG, and Raytheon Technologies Corp. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>>
Shares of
Johnson & Johnson
have modestly outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+7.4% vs. +6.7%). The company’s pharma unit is performing at above-market levels, supported by its blockbuster drugs, Darzalex and Stelara, and contribution from newer drugs, Erleada and Tremfya. Sales in the MedTech unit recovered in Q1 and the company is focusing on growing this business through new products.
However, sales in the Consumer unit are being hurt by external supply constraints. J&J is making rapid progress with its pipeline and line extensions. Headwinds like generic competition and pricing pressure continue. Though J&J has taken meaningful steps to resolve its talc and opioid litigation, they continue to remain an overhang on the stock.
(You can
read the full research report on Johnson & Johnson here >>>
)
Roche
shares have gained +17.4% over the past year against the Zacks Large Cap Pharmaceuticals industry’s gain of +28.8%. The company’s strong demand for coronavirus tests, recently launched drugs and diagnostics platforms has led to a strong performance. The Zacks analyst believes that the core pharmaceuticals business is showing signs of recovery from COVID-19 disruptions. The diagnostics division maintains its stellar performance on strong demand for COVID-19 tests and other diagnostics platforms.
Strong growth in Ocrevus, Evrysdi, Tecentriq and Hemlibra continues to counter biosimilar competition for legacy drugs like Herceptin, Avastin and MabThera. Approval of new drugs should also boost the top line. However, biosimilar competition for key drugs weighs on its performance. The decline in sales of legacy drugs due to generic competition has also affected revenues.
(You can
read the full research report on Roche here >>>
)
Shares of
Raytheon
have outperformed the Zacks Aerospace – Defense Equipment industry over the past year (+33.9% vs. +17.8%). The company continues to receive ample orders for its combat-proven defense products from the Pentagon. The Zacks analyst believes that both domestic and international program growth to remain robust for its defense business in the coming days. The SEAKR Engineering acquisition is expected to bolster Raytheon’s space-based capabilities and would bring in improved synergies.
The stock holds a solid solvency position, at least in the near term. However, the outbreak of the Omicron variant has once again impacted demand in the commercial aerospace market, which in turn may hurt Raytheon’s Pratt & Whitney and Collins Aerospace segments. Purchase order declines also pose a risk to the stock.
(You can
read the full research report on Raytheon here >>>
)
Other noteworthy reports we are featuring today include Intuit Inc. and Target Corp.
Why Haven’t You Looked at Zacks’ Top Stocks?
Our 5 best-performing strategies have blown away the S&P’s impressive +28.8% gain in 2021. Amazingly, they soared
+40.3%, +48.2%, +67.6%, +94.4%,
and
+95.3%
. Today you can access their live picks without cost or obligation.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance
for information about the performance numbers displayed in this press release.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
